Comparing Patients After ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin - Full Text View

Comparing Patients After ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin

This study is not yet open for participant recruitment.
Verified by Hadassah Medical Organization, May 2007

Sponsored by:	Hadassah Medical Organization
Information provided by:	Hadassah Medical Organization
ClinicalTrials.gov Identifier:	NCT00478998

Purpose

The purpose of this study is to see whether patients undergoing ESWL, for upper tract urinary stones between 1.5-2.0cm, may be treated by expulsion therapy(Tamsulosin) instead of inserting ureteral stents .

Condition	Intervention	Phase
Upper Tract Ureterolithiasis	Drug: Tamsulosin	Phase II

ChemIDplus related topics:

Tamsulosin Tamsulosin hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment

Official Title:	Phase II Study Comparing Two Groups of Patients Undergoing ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:

stone status at 3 month .
stone free

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Patients above 18 yrs of age.
Single urolithiasis up to 2 cm.
Kidney/ureters that haven't undergone previous ESWL or stent insertion.
Normal renal function (creatinine below 100mmo1/1).
Sterile urine culture.
Normal CBC, blood electrolytes and coagulation studies.
Radioopaque stones.

Exclusion Criteria:

More than one stone per kidney unit.
Patients receiving steroids, NSAIDS, calcium channel blockers or alpha blockers on a regular basis.
Anatomical anomalies or uromechanical obstruction.
Single kidney.
Cystinuria.
Soldiers or pregnant women.
Patients under 18 year

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00478998

Contacts


Contact: Mordechai Duvdevani, MD	0508946816	moti_duv@yahoo.com

Contact: Shilo Rosenberg, MD	0508946036	shilo_inbar@bezeqint.net

Locations


Israel
	Hadassah Medical Organization	Not yet recruiting
	Jerusalem, Israel, 91120
	Contact: Mordechai Duvdevani, MD 0508946816 moti_duv@yahoo.com
	Principal Investigator: Mordechai Duvdevani, MD

Sponsors and Collaborators

Hadassah Medical Organization

Investigators


Principal Investigator:	Mordechai Duvdevani, MD	Hadassah Medical Organization

More Information

Study ID Numbers:	890pal- HMO-CTIL
First Received:	May 24, 2007
Last Updated:	May 24, 2007
ClinicalTrials.gov Identifier:	NCT00478998
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:

expulsion therapy

tamsulosin

ureterolithiasis

stents

Study placed in the following topic categories:

Pathological Conditions, Anatomical

Urinary Calculi

Ureterolithiasis

Urologic Diseases

Urolithiasis

Tamsulosin

Ureteral Diseases

Ureteral Calculi

Calculi

Additional relevant MeSH terms:

Neurotransmitter Agents

Molecular Mechanisms of Pharmacological Action

Adrenergic Agents

Antineoplastic Agents

Therapeutic Uses

Physiological Effects of Drugs

Adrenergic Antagonists

Adrenergic alpha-Antagonists

Pharmacologic Actions

ClinicalTrials.gov processed this record on September 05, 2008